These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 29866903)
21. The cysteine desulfurase IscS of Mycobacterium tuberculosis is involved in iron-sulfur cluster biogenesis and oxidative stress defence. Rybniker J; Pojer F; Marienhagen J; Kolly GS; Chen JM; van Gumpel E; Hartmann P; Cole ST Biochem J; 2014 May; 459(3):467-78. PubMed ID: 24548275 [TBL] [Abstract][Full Text] [Related]
22. Use of probiotics in prevention and treatment of patients with Clostridium difficile infection. Ollech JE; Shen NT; Crawford CV; Ringel Y Best Pract Res Clin Gastroenterol; 2016 Feb; 30(1):111-8. PubMed ID: 27048902 [TBL] [Abstract][Full Text] [Related]
23. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Džunková M; D'Auria G; Xu H; Huang J; Duan Y; Moya A; Kelly CP; Chen X Front Cell Infect Microbiol; 2016; 6():119. PubMed ID: 27757389 [TBL] [Abstract][Full Text] [Related]
24. Updates on Clostridium difficile spore biology. Gil F; Lagos-Moraga S; Calderón-Romero P; Pizarro-Guajardo M; Paredes-Sabja D Anaerobe; 2017 Jun; 45():3-9. PubMed ID: 28254263 [TBL] [Abstract][Full Text] [Related]
25. Non-conventional antimicrobial and alternative therapies for the treatment of Clostridium difficile infection. Roshan N; Hammer KA; Riley TV Anaerobe; 2018 Feb; 49():103-111. PubMed ID: 29309845 [TBL] [Abstract][Full Text] [Related]
26. A new strategy for the prevention of Clostridium difficile infection. Howerton A; Patra M; Abel-Santos E J Infect Dis; 2013 May; 207(10):1498-504. PubMed ID: 23420906 [TBL] [Abstract][Full Text] [Related]
27. Molecular basis of function and the unusual antioxidant activity of a cyanobacterial cysteine desulfurase. Banerjee M; Chakravarty D; Ballal A Biochem J; 2017 Jul; 474(14):2435-2447. PubMed ID: 28592683 [TBL] [Abstract][Full Text] [Related]
28. Recurrence of dual-strain Clostridium difficile infection in an in vitro human gut model. Crowther GS; Chilton CH; Todhunter SL; Nicholson S; Freeman J; Wilcox MH J Antimicrob Chemother; 2015 Aug; 70(8):2316-21. PubMed ID: 25925596 [TBL] [Abstract][Full Text] [Related]
30. Outcome of relapsing Clostridium difficile infections do not correlate with virulence-, spore- and vegetative cell-associated phenotypes. Plaza-Garrido Á; Miranda-Cárdenas C; Castro-Córdova P; Olguín-Araneda V; Cofré-Araneda G; Hernández-Rocha C; Carman R; Ibáñez P; Fawley WN; Wilcox MH; Gil F; Calderón IL; Fuentes JA; Guzmán-Durán AM; Alvarez-Lobos M; Paredes-Sabja D Anaerobe; 2015 Dec; 36():30-8. PubMed ID: 26403333 [TBL] [Abstract][Full Text] [Related]
31. A combination of the probiotic and prebiotic product can prevent the germination of Clostridium difficile spores and infection. Rätsep M; Kõljalg S; Sepp E; Smidt I; Truusalu K; Songisepp E; Stsepetova J; Naaber P; Mikelsaar RH; Mikelsaar M Anaerobe; 2017 Oct; 47():94-103. PubMed ID: 28465256 [TBL] [Abstract][Full Text] [Related]
32. Neutralization of macrophage migration inhibitory factor improves host survival after Clostridium difficile infection. Jose S; Mukherjee A; Abhyankar MM; Leng L; Bucala R; Sharma D; Madan R Anaerobe; 2018 Oct; 53():56-63. PubMed ID: 29944928 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model. Baines SD; Noel AR; Huscroft GS; Todhunter SL; O'Connor R; Hobbs JK; Freeman J; Lovering AM; Wilcox MH J Antimicrob Chemother; 2011 Jul; 66(7):1537-46. PubMed ID: 21504940 [TBL] [Abstract][Full Text] [Related]
34. Structural and functional changes within the gut microbiota and susceptibility to Clostridium difficile infection. Ross CL; Spinler JK; Savidge TC Anaerobe; 2016 Oct; 41():37-43. PubMed ID: 27180006 [TBL] [Abstract][Full Text] [Related]
35. Clostridium difficile flagella induce a pro-inflammatory response in intestinal epithelium of mice in cooperation with toxins. Batah J; Kobeissy H; Bui Pham PT; Denève-Larrazet C; Kuehne S; Collignon A; Janoir-Jouveshomme C; Marvaud JC; Kansau I Sci Rep; 2017 Jun; 7(1):3256. PubMed ID: 28607468 [TBL] [Abstract][Full Text] [Related]
36. Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model. Chilton CH; Freeman J; Crowther GS; Todhunter SL; Nicholson S; Wilcox MH J Antimicrob Chemother; 2012 Apr; 67(4):951-4. PubMed ID: 22279183 [TBL] [Abstract][Full Text] [Related]
37. The role of gut microbiota in Clostridium difficile infection. Samarkos M; Mastrogianni E; Kampouropoulou O Eur J Intern Med; 2018 Apr; 50():28-32. PubMed ID: 29428498 [TBL] [Abstract][Full Text] [Related]
38. Characterization of Chicken IgY Specific to Pizarro-Guajardo M; Díaz-González F; Álvarez-Lobos M; Paredes-Sabja D Front Cell Infect Microbiol; 2017; 7():365. PubMed ID: 28856119 [No Abstract] [Full Text] [Related]
39. Predictive values of models of Clostridium difficile infection. Chilton CH; Freeman J Infect Dis Clin North Am; 2015 Mar; 29(1):163-77. PubMed ID: 25582644 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model. Baines SD; Chilton CH; Crowther GS; Todhunter SL; Freeman J; Wilcox MH J Antimicrob Chemother; 2013 Aug; 68(8):1842-9. PubMed ID: 23557928 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]